Diana M. Gibb

19.7k total citations · 2 hit papers
334 papers, 11.1k citations indexed

About

Diana M. Gibb is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Diana M. Gibb has authored 334 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 256 papers in Infectious Diseases, 127 papers in Virology and 92 papers in Epidemiology. Recurrent topics in Diana M. Gibb's work include HIV/AIDS Research and Interventions (212 papers), HIV/AIDS drug development and treatment (136 papers) and HIV Research and Treatment (127 papers). Diana M. Gibb is often cited by papers focused on HIV/AIDS Research and Interventions (212 papers), HIV/AIDS drug development and treatment (136 papers) and HIV Research and Treatment (127 papers). Diana M. Gibb collaborates with scholars based in United Kingdom, Uganda and Zimbabwe. Diana M. Gibb's co-authors include Abdel G. Babiker, A. Sarah Walker, Avy Violari, Shabir A. Madhi, Patrick Jean‐Philippe, James McIntyre, Mark F. Cotton, Jan Steyn, Mike Sharland and A Sarah Walker and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Diana M. Gibb

324 papers receiving 10.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early Antiretroviral Therapy and Mortality among HIV-Infected Infants

2008 1.0k citations Avy Violari, Diana M. Gibb et al. profile →
Mortality after Fluid Bolus in African Children with Severe Infection

2011 958 citations Kathryn Maitland, Sarah Kiguli et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Diana M. Gibb United Kingdom	50	7.5k	3.8k	3.7k	2.1k	1.4k	334	11.1k
Andrew Boulle South Africa	52	7.6k 1.0×	3.8k 1.0×	2.9k 0.8×	1.2k 0.6×	1.1k 0.8×	259	9.2k
Valériane Leroy France	48	5.3k 0.7×	2.9k 0.8×	2.1k 0.6×	1.2k 0.6×	1.1k 0.8×	283	7.8k
François Dabis France	65	12.2k 1.6×	5.9k 1.6×	5.9k 1.6×	4.7k 2.2×	1.4k 1.0×	415	16.1k
Hoosen Coovadia South Africa	46	4.7k 0.6×	3.3k 0.9×	2.1k 0.6×	1.2k 0.6×	885 0.6×	158	7.7k
Jeffrey S. A. Stringer United States	46	4.7k 0.6×	2.6k 0.7×	1.4k 0.4×	1.1k 0.5×	1.6k 1.1×	256	7.4k
Edwin D. Charlebois United States	55	8.7k 1.2×	4.2k 1.1×	2.5k 0.7×	1.1k 0.5×	725 0.5×	214	11.0k
Jean B. Nachega United States	57	9.1k 1.2×	3.9k 1.0×	2.6k 0.7×	1.5k 0.7×	848 0.6×	193	11.6k
Lynne Mofenson United States	62	12.5k 1.7×	5.7k 1.5×	5.8k 1.6×	3.3k 1.6×	1.5k 1.1×	277	15.3k
Olivia Keiser Switzerland	42	4.9k 0.7×	2.7k 0.7×	2.0k 0.5×	1.0k 0.5×	767 0.6×	200	7.0k
Gary Maartens South Africa	62	10.4k 1.4×	6.5k 1.7×	2.9k 0.8×	1.5k 0.7×	947 0.7×	376	14.0k

Countries citing papers authored by Diana M. Gibb

Since Specialization

Citations

This map shows the geographic impact of Diana M. Gibb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana M. Gibb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana M. Gibb more than expected).

Fields of papers citing papers by Diana M. Gibb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana M. Gibb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana M. Gibb. The network helps show where Diana M. Gibb may publish in the future.

Co-authorship network of co-authors of Diana M. Gibb

This figure shows the co-authorship network connecting the top 25 collaborators of Diana M. Gibb. A scholar is included among the top collaborators of Diana M. Gibb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana M. Gibb. Diana M. Gibb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Waalewijn, Hylke, Alexander J. Szubert, Roeland E. Wasmann, et al.. (2023). First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. Clinical Infectious Diseases. 77(6). 875–882. 7 indexed citations

Frigati, Lisa, Diana M. Gibb, Joseph I. Harwell, et al.. (2023). The hard part we often forget: providing care to children and adolescents with advanced HIV disease. Journal of the International AIDS Society. 26(3). e26041–e26041. 4 indexed citations

Ades, A. E., Fabiana Gordon, Karen Scott, et al.. (2022). Overall Vertical Transmission of Hepatitis C Virus, Transmission Net of Clearance, and Timing of Transmission. Clinical Infectious Diseases. 76(5). 905–912. 21 indexed citations

Ades, A. E., Fabiana Gordon, Karen Scott, et al.. (2022). Spontaneous Clearance of Vertically Acquired Hepatitis C Infection: Implications for Testing and Treatment. Clinical Infectious Diseases. 76(5). 913–991. 17 indexed citations

Chabala, Chishala, Anna Turkova, Anneke C. Hesseling, et al.. (2021). Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations. Clinical Infectious Diseases. 74(10). 1767–1775. 17 indexed citations

Maitland, Kathryn, Sarah Kiguli, Peter Olupot‐Olupot, et al.. (2021). Transfusion management of severe anaemia in African children: a consensus algorithm. British Journal of Haematology. 193(6). 1247–1259. 15 indexed citations

McIlleron, Helen, David M. Burger, Diana M. Gibb, et al.. (2021). Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications. British Journal of Clinical Pharmacology. 88(2). 403–415. 2 indexed citations

Ssengooba, Willy, Lydia Nakiyingi, Eric Wobudeya, et al.. (2020). Accuracy of Xpert Ultra in Diagnosis of Pulmonary Tuberculosis among Children in Uganda: a Substudy from the SHINE Trial. Journal of Clinical Microbiology. 58(9). 22 indexed citations

Lyttle, Mark D, Julia Bielicki, David Dunn, et al.. (2019). Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomIsed controlled Trial (CAP-IT). BMJ Open. 9(5). e029875–e029875. 7 indexed citations

10.

Kiwuwa-Muyingo, Sylvia, George Abongomera, Ivan Mambule, et al.. (2019). Lessons for test and treat in an antiretroviral programme after decentralisation in Uganda: a retrospective analysis of outcomes in public healthcare facilities within the Lablite project. International Health. 12(5). 429–443. 4 indexed citations

11.

Payne, Helen, Stuart Adams, Patricia Hunter, et al.. (2018). Naive B Cell Output in HIV-Infected and HIV-Uninfected Children. AIDS Research and Human Retroviruses. 35(1). 33–39. 2 indexed citations

12.

Abongomera, George, Sylvia Kiwuwa-Muyingo, Paul Revill, et al.. (2017). Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys. International Health. 9(2). 91–99. 8 indexed citations

13.

Cook, Adrian, Lubbe Wiesner, Veronica Mulenga, et al.. (2016). Effect of diurnal variation,CYP2B6genotype and age on the pharmacokinetics of nevirapine in African children. Journal of Antimicrobial Chemotherapy. 72(1). 190–199. 8 indexed citations

14.

Kenny, Julia, Victor Musiime, Ali Judd, & Diana M. Gibb. (2012). Recent advances in pharmacovigilance of antiretroviral therapy in HIV-infected and exposed children. Current Opinion in HIV and AIDS. 7(4). 305–316. 9 indexed citations

15.

Gibb, Diana M., E. C. Russell, Ennie Chidziva, et al.. (2012). Pregnancy and Infant Outcomes among HIV-Infected Women Taking Long-Term ART with and without Tenofovir in the DART Trial. PLoS Medicine. 9(5). e1001217–e1001217. 111 indexed citations

16.

Castro, Hannah, Alexandra Compagnucci, Carlo Giaquinto, et al.. (2011). First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. The Lancet Infectious Diseases. 11(4). 273–283. 101 indexed citations

17.

Foster, Caroline, Ali Judd, P Tookey, et al.. (2009). Young People in the United Kingdom and Ireland with Perinatally Acquired HIV: The Pediatric Legacy For Adult Services. AIDS Patient Care and STDs. 23(3). 159–166. 62 indexed citations

18.

Gibb, Diana M.. (2001). Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. Archives of Disease in Childhood. 84(3). 230–236. 19 indexed citations

19.

Gibb, Diana M., J. Masters, Ezia Ruga, et al.. (1996). Persistence of Antibody Responses to Haemophilus influenzae Type b Polysaccharide Conjugate Vaccine in Children with Vertically Acquired Human Immunodeficiency Virus Infection. The Pediatric Infectious Disease Journal. 15(12). 1097–1101. 29 indexed citations

20.

Gibb, Diana M., et al.. (1992). Guidelines for management of children with HIV infection. OpenGrey (Institut de l'Information Scientifique et Technique). 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact